# Calithera Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calithera-biosciences

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.calithera.com
- Total disclosed funding: $81M
- Latest round: Series D (Oct 29, 2013)
- Investors on record: 7

## About

Calithera Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment through targeted approaches and personalized medicine solutions.Founded in 2010 and headquartered in San Francisco, US, Calithera Biosciences, Inc. specializes in developing cancer therapies. The company launched its IPO on October 2, 2014, raising USD 80.00 mn by selling 8 million shares at a price of USD 10 per share. CEO Susan Molineaux has been pivotal in leading the firm since its inception, steering it towards a focused approach in oncology. All venture capital investors have exited their stake in the firm, marking a significant transition in its business model.Calithera Biosciences, Inc. develops targeted therapies aimed at treating cancer, focusing on small molecule drugs that inhibit metabolic pathways in tumors. Their portfolio includes innovative compounds that are in various stages of clinical trials, addressing specific types of cancer and enhancing treatment outcomes for patients.In the most recent fiscal year of 2021, Calithera Biosciences, Inc. reported a revenue of USD 9.75 mn. The company demonstrated a negative EBITDA of USD 41.82 mn for the year 2022, reflecting the ongoing investments in research and development of its therapeutic offerings.Calithera Biosciences, Inc. aims to expand its oncology product pipeline with new therapies targeting additional cancer types in the coming years. The firm plans to leverage its recent IPO funding of USD 80.00 mn to accelerate research and development efforts and facilitate entry into emerging markets in Asia and Europe by 2025. Recent strategic moves indicate a focus on enhancing partnerships with other pharmaceutical companies to broaden its product offerings and increase market penetration.

## Funding rounds

- Series D, Oct 29, 2013, $35M — Advanced Technology Ventures, Delphi Ventures, Morgenthaler Ventures, Adage Capital Management, Longwood Fund
- Series C, Dec 19, 2012, $2M — Advanced Technology Ventures, Delphi Ventures, Morgenthaler Ventures
- Series B, Nov 9, 2011, $4M — Advanced Technology Ventures, Delphi Ventures, Morgenthaler Ventures, US Venture Partners
- Series A, Jul 8, 2010, $40M — Advanced Technology Ventures, Delphi Ventures, Morgenthaler Ventures, US Venture Partners, Mission Bay Capital

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series C, Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series A, Series B, Series C, Series D
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series A, Series B, Series C, Series D
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A
- Adage Capital Management — Series D
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series D